Praktické lékárenství, 2019, E-verze 3/19
Current pharmacotherapy
Selected biological drugs in non-oncological indications
Petra Matalová
Prakt. Lékáren. 2019; 15(3e): 15-27 
Progress in developing new monoclonal antibodies allows us to affect pathological immune processes on many different levels. For treatmentof different diseases, we now have available monoclonal antibodies. Also, the development of new humanized and human antibodies causedsignificant improvement of their safety profile. This article briefly summarizes the antibodies used in non-oncological indications.
Current pharmacotherapy of tuberculosis
Jiří Wallenfels, Martina Vašáková, Ivan Solovič
Prakt. Lékáren. 2019; 15(3e): 28-36
Tuberculosis still represents global threat, with respect both to the number of infected, ill and dead individuals. Increasing incidence of resistantforms of tuberculosis with significantly worse treatment outcomes compared with sensitive tuberculosis poses a concern. New antituberculoticsand antibiotics prescribed until now mainly for other infections are starting to be used for treatment of resistant tuberculosis. New,more effective, shorter and better tolerated treatment coarses are investigated. The current epidemiologic situation in the Czech Republic is relatively favourable, it is appropriate to discuss about the obligation...
Multiple sclerosis – maternity and breastfeeding
Olga Zapletalová
Prakt. Lékáren. 2019; 15(3e): 37-43
Multiple sclerosis (MS) is disease induced by immunopathogenetic autoimmune inflammation and neurodegenerative process, which demage central nervous system. The young women of childbearing age are mostly affected by MS. Biological role of women is fullfiled by maternity and their wish to have a child is also common for women with MS. Conception, pregnancy and delivery is immunological action and maternal immune system undergoes great changes. Brestfeeding is greatly important for optimal development of the newborn in the first months after delivery. The hormonal changes during brestfeeding are positively modulating the autoimmune reactivity of MS females...
Medicamenta nova
Antibody-Drug Conjugates
Miroslav Miletín
Prakt. Lékáren. 2019; 15(3e): 3-14
Monoclonal Antibodies (MAbs) belong among the fastest growing types of biologics for a variety of different indications and employing different mechanisms of action. The trend in the development of new MAbs is to modify their basic structure, leading to an improvement in the therapeutic profile or at least pharmacokinetic properties. In addition to the basic types of antibodies, their biosynthetic and semi-synthetic modifications are currently available for clinical use. Biosynthetic interventions include e.g. changes in the sugar moiety of the molecule, or the changes of several amino acids in constant regions of the MAb. Variable antibody fragments...